A multicenter open label study to compare efficacy and safety of induction treatment by thymoglobulin (ATG) versus daclizumab (anti-IL-2R) with a triple drug regimen (tacrolimus, mycophenolate mofetil, prednisone) in high risk renal transplant recipients.
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Antithymocyte globulin (Primary) ; Daclizumab (Primary) ; Mycophenolate mofetil; Prednisone; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms TAXI
- 08 Jul 2011 New source added and integrated (Australian New Zealand Clinical Trials Registry, ACTRN12610000071022).
- 12 Jun 2008 New trial record.